OR WAIT null SECS
October 21, 2022
AAPS will exclusively advise RX Global on scientific focus areas for Interphex 2023, which is set to take place at the Javits Center in New York City next spring.
Aenova Group and Microcaps are partnering to enable new customized formulations for product development and life cycle management solutions.
The agency has recommended approval of Comirnaty and Spikevax for children from six months of age.
The agency has recommended authorization of the Spikevax COVID-19 vaccine that targets the Omicron variants BA.4 and BA.5.
October 19, 2022
Gilead and MacroGenics will work together on bispecific antibodies for the treatment of blood cancers.
Ebvallo (tabelecleucel) would be the first EMA-approved therapy for patients with relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease.
Takeda’s dengue vaccine is designed to prevent disease caused by virus serotypes 1, 2, 3, and 4 in individuals four and older.
October 14, 2022
Merck has exercised a $250 million option with Moderna to jointly develop and commercialize cancer vaccine mRNA-4157/V940.
Alexion’s acquisition of LogicBio is designed to accelerate the company’s growth in genomic medicines.
October 13, 2022
FDA amended its authorization for the Moderna and Pfizer-BioNTech bivalent booster vaccines to permit their use in children as young as five years old.